Trial · NCT01797029
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Vaccine-matched Strains). | Through 7 to 9 months post-vaccination | |
| Secondary | Safety Profile of LAIV: Solicited and Unsolicited Local and Systemic Reactions | Through one week post-vaccination | |
| Secondary | Safety Profile of LAIV: Immediate Reactions | 30 minutes post-vaccination | |
| Secondary | Safety Profile of LAIV: Serious Adverse Events | Through 7 to 9 months post-vaccination | |
| Secondary | Safety Profile of LAIV: Protocol Defined Wheezing Illness | Through 7 to 9 months post-vaccination | |
| Secondary | Percentage of Participants With Symptomatic, Laboratory-confirmed, Influenza Virus Infection (All Strains) | Through 7 to 9 months post-vaccination | |
| Secondary | The Clinical Characteristics of Influenza, Including Influenza Co-infections With Other Bacterial and Viral Respiratory Pathogens | Through 16 to 19 months post-vaccination | |
| Secondary | The Viral Etiologies of Acute Respiratory and Febrile Illness | Through 16 to 19 months post-vaccination | |
| Secondary | Safety Profile of LAIV: Serious Adverse Events | Through 16 to 19 months post-vaccination | |
| Secondary | Safety Profile of LAIV: Protocol Defined Wheezing Illness | Through 16 to 19 months post-vaccination | |
| Secondary | Percentage of Participants With Symptomatic, Laboratory-confirmed, Influenza Virus Infection (All Strains) | Through 16 to 19 months post-vaccination | |
| Secondary | Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Vaccine-matched Strains). | Through 16 to 19 months post-vaccination | |
| Other | Percentage of Participants With Moderate to Severe, Laboratory-confirmed Influenza Virus Infection Among Children | Through 7 to 9 months post-vaccination | |
| Other | Percentage of Participants With Moderate to Severe, Laboratory-confirmed Influenza Virus Infection Among Children | Through 16 to 19 months post-vaccination | |
| Other | Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Vaccine-matched Strains) Among Children | From approx. 6 months to approximately 19 months post-vaccination | |
| Other | Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (All Strains) Among Children | From approx. 6 months to approximately 19 months post-vaccination |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01797029/registered